title: Early postoperative thrombosis of an aortic bioprosthetic valve: should anticoagulation be patient specific?
abstract: Optimal antithrombotic recommendations for patients following bioprosthetic aortic valve replacement have yet to be decided. Current guidelines present conflicting opinions and are based on historical studies, which are limited by their design. We review comparative studies investigating differing thromboprophylactic regimes and outcomes for bioprosthetic aortic valve replacement.
authors.affiliation: Department of Cardiothoracic Surgery, Leeds General Infirmary, Leeds, UK.
authors.forename: Christopher Andrew
authors.initials: CA
authors.lastname: Efthymiou
authors.forename: Rosalind Jane
authors.initials: RJ
authors.lastname: Mills
authors.forename: David John
authors.initials: DJ
authors.lastname: O'Regan
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D001021:Aortic Valve / Q000601:surgery*; D001024:Aortic Valve Stenosis / Q000601:surgery*; D001241:Aspirin / Q000008:administration & dosage*; D001705:Bioprosthesis; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D011183:Postoperative Complications / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011475:Prosthesis Failure / Q000009:adverse effects; D012086:Reoperation; D013927:Thrombosis / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin; D001241:Aspirin